June 2, 2025
Source: drugdu
83
The reporter learned from Fosun Pharma on May 28 that the company recently reached an agreement with Jiuyuan Gene on a number of biological drugs and innovative drugs.A signing ceremony for the exclusive overseas commercialization rights cooperation of medical products was held in Hangzhou.
According to the agreement, Fosun Pharma obtained exclusive authorization from Jiuyuan Gene for the exclusive clinical development, registration, production and commercialization rights of products such as semaglutide, Bone Youdao and JY-23 in all countries in the Middle East and North Africa, sub-Saharan Africa and some ASEAN countries.
Chen Yuqing, Chairman of Fosun Pharma, said: "We are very pleased to work with Jiuyuan Gene to promote the development and commercialization of multiple biopharmaceuticals and innovative medical devices in overseas markets. This cooperation is not only a deep synergy of the technical strength and resource endowment of both parties, but also aThis is another important milestone in our globalization strategy. In the future, we look forward to continuously promoting the launch of innovative products overseas through cooperation and joint efforts between the two parties, solving unmet clinical needs, and benefiting more patients around the world.”
At present, Fosun Pharma's core business has mainly covered overseas markets such as the United States, Europe, Africa, India and Southeast Asia, and continues to implement its internationalization strategy in multiple dimensions such as innovative research and development, licensing cooperation, production operations and commercialization. In 2024, Fosun Pharma's overseas revenue will be 11.297 billion yuan, accounting for 27.51% of its revenue.
In the African and Middle Eastern markets, Fosun Pharma has built a mature commercial network. Among them, Fosun Pharma's sales network in the African market has covered more than 40 countries and regions, mainly conducting pharmaceutical product export and distribution business in the English-speaking and French-speaking regions south of the Sahara Desert; in the Middle East market, in April 2025, Fosun Pharma reached a strategic cooperation with Saudi Arabia's leading comprehensive healthcare group Fakeeh Care Group, and will jointly promote the implementation of a number of leading therapies including biological drugs and CAR-T cell therapy in Saudi Arabia. In November 2024, Fosun Pharma's holding subsidiary Henlius reached a strategic cooperation with SVAX. The two parties plan to establish a new joint venture in Saudi Arabia to jointly enhance the accessibility of innovative and high-value products in the MENAT region (Middle East, North Africa, Turkey).
https://finance.eastmoney.com/a/202505293417988794.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.